Prediction of significant fibrosis and cirrhosis in hepatitis B e‐antigen negative patients with chronic hepatitis B using routine parameters

Abstract

Our model can accurately predict both significant fibrosis and cirrhosis and may decrease the need of liver biopsy in a considerable proportion of patients with HBeAg negative CHB.

The Diagnostic Value of the FIB-4 Index for Staging Hepatitis B-Related Fibrosis: A Meta-Analysis

“…ΔThe disease spectrum of some studies [11], [17], [19]–[21], [24], [26]–[28] were not in good accordance with our study, thus they were excluded for sensitivity analysis.…”

“…Despite this limitation, these factors were assessed in meta-regression for exploring sources of heterogeneity. The disease spectrum of 9 studies [11], [17], [19]–[21], [24], [26]–[28] were not in good accordance with our study and were excluded for further sensitivity analysis. Specifically, three of these studies [20], [24], [27] focused on patients with limited ALT (normal or less than 2× upper limit of normal), one focused on Hepatitis B virus e antigen (HBeAg)-positive patients [28], one focused on HBeAg-negative patients [26], one defined the urea nitrogen limitation when collecting samples [11], one included patients after therapy [19], one only included inpatients [17], and one did not describe the objective of the study clearly [21].…”

“…ΔThe disease spectrum of some studies [11], [17], [19]–[21], [24], [26]–[28] were not in good accordance with our study, thus they were excluded for sensitivity analysis.*The studies in which the reference standard results were interpreted without knowledge of the results of the index tests, were grouped into “Blindness”.The “proper interval” was defined as the time interval between the determination of the FIB-4 index and liver biopsy was no longer than 7 days.#As two studies [22], [32] were written by the same author, the study [32] with the smaller sample size was excluded for sensitivity analysis. 95% CI: 95% confidence interval.…”

A Chinese Herbal Medicine, Jia-Wei-Xiao-Yao-San, Prevents Dimethylnitrosamine-Induced Hepatic Fibrosis in Rats

“…The pathway for the progression to liver cirrhosis is the fibrotic process in the liver of patients with the aforementioned risk factors [16, 17]. Therefore, antifibrotic therapy for chronic hepatitis is a crucial topic.…”

Karaciğer Fibrozisinin İnvazif Olmayan Dolaylı Biyokimyasal Belirteçleri

“…Son yaklaşımlarda birden fazla biyokimyasal belirtecin kombine edilmesinin [36][37][38][39][40] bu hastalardaki tanısal doğruluğu arttıracağı ileri sürülmüştür. Ayrıca, yapılan çalışmalar incelendiğinde siroz hastalarında dolaylı biyokimyasal belirteçlerin daha iyi bir performansa sahip olduğu dikkatimizi çekmiştir 20,25,37,[40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59] . Son yıllarda yapılan çalışmalarda karaciğer biyopsisinden önce biyokimyasal testlerin ve indekslerin birinci basamak tarama testi olarak kullanılmasının özellikle belirgin fibrozis ve sirozun tespiti ve dışlanmasında doğru yol gösterici olup gereksiz karaciğer biyopsisi yapılmasını önleyebileceği vurgulanmıştır.…”